secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001193125-24-066825
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics reports Q4 2023 net income of $51.2M; SPR720 topline data expected 2H 2024
--------------------------------------------------------------------------------

- Q4 2023 net income of $51.2M ($0.96 diluted EPS) vs $26.8M in Q4 2022; full-year net income of $22.8M ($0.43 diluted EPS).
- Total revenue $73.5M in Q4 2023, up from $47.4M in Q4 2022, driven by $71.8M in GSK/Pfizer collaboration revenue.
- Cash and cash equivalents $76.3M at Dec 31, 2023; received $23.8M first tranche of $95M GSK milestone, expects cash runway into late 2025.
- SPR720 Phase 2a proof-of-concept topline data in NTM-PD expected in second half of 2024; Phase 3 PIVOT-PO trial for tebipenem HBr enrolling.
- Sath Shukla transitioned to President & CEO in August 2023; Esther Rajavelu appointed CFO/CBO in November 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524066825/0001193125-24-066825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524066825/d809069d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-066825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer